Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5QSKN)

• Drug Name: INDOPROFEN Drug Info
• Synonyms: Dexindoprofen; UNII-004T8726AU; 53086-13-8; 004T8726AU; (+)-indoprofen; Dexindoprofenum; Dexindoprofene; Dexindoprofeno; Dexindoprofen [INN]; Dexindoprofenum [INN-Latin]; Dexindoprofene [INN-French]; Dexindoprofeno [INN-Spanish]; Indoprofen (+)-; EINECS 258-351-2; AC1Q5QZO; AC1L2A9M; ZINC391; SCHEMBL286896; (+)-(S)-4-(1-Oxo-2-isoindolinyl)hydratropasaeure; CHEMBL2106252; AJ-07888; (+)-(S)-p-(1-Oxo-2-isoindolinyl)hydratropic acid; UNII-CPE46ZU14N component RJMIEHBSYVWVIN-NSHDSACASA-N

Indication

Disease Entry	ICD 11	Status	REF
Gout	FA25	Withdrawn from market	[1]

• Cross-matching ID:
  PubChem CID: 3718
  ChEBI ID: CHEBI:76162
  CAS Number: CAS 31842-01-0
  TTD Drug ID: DM5QSKN

Molecule-Related Drug Atlas

Drug(s) Targeting C-X-C chemokine receptor type 1 (CXCR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[2]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[2]
SCH-527123	DMPUAOE	Chronic obstructive pulmonary disease	CA22	Phase 2	[6]
SX-682	DMHMG6X	Melanoma	2C30	Phase 1	[7]
R-ketoprofen	DMHSUQ1	N. A.	N. A.	Discontinued in Phase 2	[2]
2-(3-Isopropyl-phenyl)-propionic acid	DMUOWNE	Discovery agent	N.A.	Investigative	[2]
2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid	DMWIUR0	Discovery agent	N.A.	Investigative	[2]
(R)-2-(4-Isobutyl-phenyl)-propionamide	DMBQ0PR	Discovery agent	N.A.	Investigative	[2]
(R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide	DMWRIQG	Discovery agent	N.A.	Investigative	[2]
2-[3-(2-Methyl-butyl)-phenyl]-propionic acid	DMKSDT4	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting C-X-C chemokine receptor type 2 (CXCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[2]
Clotrimazole	DMMFCIH	Cutaneous candidiasis	1F23.14	Approved	[8]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[2]
SCH-527123	DMPUAOE	Chronic obstructive pulmonary disease	CA22	Phase 2	[9]
SB-265610	DM8TKG5	Asthma	CA23	Phase 2	[10]
AZD-5069	DM3JSFK	Asthma	CA23	Phase 2	[11]
PS-938285	DMHZIFJ	Chronic obstructive pulmonary disease	CA22	Phase 2	[12]
GSK1325756	DMA6RBF	Chronic obstructive pulmonary disease	CA22	Phase 2	[13]
SB-656933	DMCY785	Chronic obstructive pulmonary disease	CA22	Phase 2	[14]
RIST4721	DMA3DKO	Hidradenitis suppurativa	ED92.0	Phase 2	[15]

Drug(s) Targeting Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[16]
Naproxen	DMZ5RGV	Bursitis		Approved	[17]
Mesalazine	DMOL5IU	Diverticulitis		Approved	[18]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[19]
Bromfenac	DMKB79O	Pain	MG30-MG3Z	Approved	[20]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[21]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[22]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[21]
Suprofen	DMKXJZ7	Miosis	LA11.62	Approved	[23]
Gamma-Homolinolenic acid	DMSXKYG	Malnutrition	5B50-5B71	Approved	[24]

Drug(s) Targeting Prostaglandin G/H synthase 2 (COX-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[25]
Naproxen	DMZ5RGV	Bursitis		Approved	[17]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[26]
Indomethacin	DMSC4A7	Bursitis		Approved	[21]
Celecoxib	DM6LOQU	Dysmenorrhea	GA34.3	Approved	[27]
Nabumetone	DMAT2XH	Osteoarthritis	FA00-FA05	Approved	[28]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[29]
Flurbiprofen	DMGN4BY	Osteoarthritis	FA00-FA05	Approved	[30]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[19]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[21]

Drug(s) Targeting Fatty acid-binding protein 1 (FABP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
FENOFIBRIC ACID	DMGO2MC	Cardiovascular disease	BA00-BE2Z	Approved	[3]
OLEIC ACID	DM54O1Z	Discovery agent	N.A.	Investigative	[3]
1-anilinonaphthalene-8-sulfonic acid	DMNGY0E	N. A.	N. A.	Investigative	[3]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[4]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[4]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[31]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[32]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[33]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[4]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[4]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[4]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[34]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[35]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 1 (CXCR1)	TTMWT8Z	CXCR1_HUMAN	Inhibitor	[2]
C-X-C chemokine receptor type 2 (CXCR2)	TT30C9G	CXCR2_HUMAN	Inhibitor	[2]
Fatty acid-binding protein 1 (FABP1)	TTIV96N	FABPL_HUMAN	Inhibitor	[3]
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[2]
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Gene/Protein Processing	[4]
UDP-glucuronosyltransferase 1A10	OTOTZVEY	UD110_HUMAN	Biotransformations	[5]
UDP-glucuronosyltransferase 1A3	OTUEOER3	UD13_HUMAN	Biotransformations	[5]
UDP-glucuronosyltransferase 1A7	OTY4JJ32	UD17_HUMAN	Biotransformations	[5]
UDP-glucuronosyltransferase 1A8	OTTMABBG	UD18_HUMAN	Biotransformations	[5]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
• [3] Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64.
• [4] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [5] Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. J Biol Chem. 2004 Jul 2;279(27):28320-9. doi: 10.1074/jbc.M401396200. Epub 2004 Apr 26.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.
• [8] Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
• [9] CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
• [10] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [11] Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
• [12] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [13] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [14] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [15] A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.
• [16] The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
• [17] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [18] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [19] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
• [20] Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
• [21] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [22] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [23] Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
• [24] Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
• [25] Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
• [26] Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
• [27] Pfizer. Product Development Pipeline. March 31 2009.
• [28] Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
• [29] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [30] Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
• [31] Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
• [32] Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
• [33] Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
• [34] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [35] Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.